Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

725 ARTÍCULOS , VIENDO DEL 316 AL 330

Home Health Management of Parkinson Disease Deep Brain Stimulation: A Randomized Clinical Trial

Duffley G, Lutz BJ, Szabo A, Wright A, Hess CW, Ramirez-Zamora A, Zeilman P, Chiu S, Foote KD, Okun MS, Butson CR.

JAMA Neurol. 2021 Aug 1;78(8):972-981. doi: 10.1001/jamaneurol.2021.1910.

[Progressive supranuclear palsy]

Fedorova NV, Bril EV, Kulua TK, Mikhaylova AD.

Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(5):111-119. doi: 10.17116/jnevro2021121051111.

Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial

Videnovic A, Amara AW, Comella C, Schweitzer PK, Emsellem H, Liu K, Sterkel AL, Gottwald MD, Steinerman JR, Jochelson P, Zomorodi K, Hauser RA.

Mov Disord. 2021 Oct;36(10):2408-2412. doi: 10.1002/mds.28702. Epub 2021 Jun 30.

Improving the diagnosis and management of Lewy body dementia: the DIAMOND-Lewy research programme including pilot cluster RCT

O’Brien JT, Taylor JP, Thomas A, Bamford C, Vale L, Hill S, Allan L, Finch T, McNally R, Hayes L, Surendranathan A, Kane J, Chrysos AE, Bentley A, Barker S, Mason J, Burn D, McKeith I.

Southampton (UK): NIHR Journals Library; 2021 Jul.

Directions of Deep Brain Stimulation for Epilepsy and Parkinson's Disease

Wu YC, Liao YS, Yeh WH, Liang SF, Shaw FZ.

Front Neurosci. 2021 Jun 14;15:680938. doi: 10.3389/fnins.2021.680938. eCollection 2021.

Bilirubin: A Promising Therapy for Parkinson's Disease

Jayanti S, Moretti R, Tiribelli C, Gazzin S.

Int J Mol Sci. 2021 Jun 9;22(12):6223. doi: 10.3390/ijms22126223.

[Non-motor symptoms in Parkinson's disease]

Nielsen NS, Skovbølling SL.

Ugeskr Laeger. 2021 Jul 5;183(27):V01210089.

Will Artificial Intelligence Replace the Movement Disorders Specialist for Diagnosing and Managing Parkinson's Disease?

Landers M, Saria S, Espay AJ.

J Parkinsons Dis. 2021;11(s1):S117-S122. doi: 10.3233/JPD-212545.

Imaging of the human subthalamic nucleus

Alkemade A, Forstmann BU.

Handb Clin Neurol. 2021;180:403-416. doi: 10.1016/B978-0-12-820107-7.00025-2.

Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial

Freire-Alvarez E, Kurča E, Lopez Manzanares L, Pekkonen E, Spanaki C, Vanni P, Liu Y, Sánchez-Soliño O, Barbato LM.

Mov Disord. 2021 Nov;36(11):2615-2623. doi: 10.1002/mds.28703. Epub 2021 Jul 8.

Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease

Magnusen AF, Hatton SL, Rani R, Pandey MK.

Front Neurol. 2021 Jun 22;12:636139. doi: 10.3389/fneur.2021.636139. eCollection 2021.

Electrophysiological biomarkers for deep brain stimulation outcomes in movement disorders: state of the art and future challenges

Bočková M, Rektor I.

J Neural Transm (Vienna). 2021 Aug;128(8):1169-1175. doi: 10.1007/s00702-021-02381-5. Epub 2021 Jul 10.

Prodromal and advanced non-motor features of Parkinson's disease

Kempster P.

BMJ Neurol Open. 2021 Jun 21;3(1):e000168. doi: 10.1136/bmjno-2021-000168. eCollection 2021.

Action Observation and Motor Imagery Improve Dual Task in Parkinson's Disease: A Clinical/fMRI Study

Sarasso E, Agosta F, Piramide N, Gardoni A, Canu E, Leocadi M, Castelnovo V, Basaia S, Tettamanti A, Volontè MA, Filippi M.

Mov Disord. 2021 Nov;36(11):2569-2582. doi: 10.1002/mds.28717. Epub 2021 Jul 19.

Bilateral Focused Ultrasound Thalamotomy for Essential Tremor (BEST-FUS Phase 2 Trial)

Iorio-Morin C, Yamamoto K, Sarica C, Zemmar A, Levesque M, Brisebois S, Germann J, Loh A, Boutet A, Elias GJB, Azevedo P, Adam E, Patel U, Lenis M, Kalia SK, Hodaie M, Fasano A, Lozano AM.

Mov Disord. 2021 Nov;36(11):2653-2662. doi: 10.1002/mds.28716. Epub 2021 Jul 20.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias